
About Newcells Biotech
Newcells Biotech is a Healthcare company based in Newcastle Upon Tyne (United Kingdom) founded in 2014. Induced pluripotent stem cell-derived organoid models are developed for research. Newcells Biotech has raised $14.43 million across 9 funding rounds from investors including Mercia, European Union and NVM Private Equity. Newcells Biotech offers products and services including Retinal Organoids, Kidney Nephron Models, and Lung Airway Models. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Assays and Drug Discovery. Its legal entity is NEWCELLS BIOTECH LIMITED.
Company details
Newcells Biotech was founded in 2014 in Newcastle Upon Tyne, United Kingdom, within the biotechnology sector. Induced pluripotent stem cell-derived organoid models are created for research applications. Off-the-shelf products, such as neural progenitor cells and cardiomyocytes, are offered alongside custom reprogramming and differentiation services. These are provided to biopharmaceutical companies and research institutions to support drug development and scientific studies.
- Total Equity Funding$14.43M (USD)
in 9 rounds
- Latest Funding Round$1.47M (USD), Series B
Dec 2024
- InvestorsMercia
& 5 more
Products & Services of Newcells Biotech
Newcells Biotech offers a comprehensive portfolio of products and services, including Retinal Organoids, Kidney Nephron Models, and Lung Airway Models.
Models for retinopathies and safety studies in drug testing
Used for toxicity and drug interaction assessments
Facilitates fibrotic disease and compound efficacy studies
Apps and channels of Newcells Biotech
its YouTube channel Newcells Biotech has 285 subscribers and 30 videos.
Videos from Newcells Biotech
The most watched videos on Newcells Biotech's YouTube channel, Newcells Biotech (285 subscribers). Click a video to play it here.
More on Newcells Biotech.
Funding Insights of Newcells Biotech
Newcells Biotech has successfully raised a total of $14.43M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $1.47 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.43M
- Total Rounds 9
- Last Round Series B β $1.47M
- Investors Count 6
All 9 funding rounds of Newcells Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $1.47M | Series B | β | β | |
| Feb 2024 | $2.95M | Series B | β | North East Fund | |
| Feb 2021 | $7.37M | Series B | β | Mercia, Northstar Ventures | β |
| Jan 2020 | $357,134 | Grant | β | β | |
| Oct 2018 | $362,460 | Grant | β | β | |
| Jul 2018 | $2.63M | Series A | β | β | |
| Jan 2018 | $362,460 | Grant | β | β | |
| Jan 2017 | $287,660 | Grant | β | β | |
| Sep 2015 | Seed | β | β |
6 investors in total: 6 institutional.
Investors in Newcells Biotech
Newcells Biotech has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Mercia, European Union and NVM Private Equity.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments are made in UK companies across diverse sectors. | northstarventures.co.uk | Newcastle Upon Tyne, United Kingdom | ||
Investment finance is provided to small and medium-sized enterprises. | northeastfund.org | Newcastle upon Tyne, United Kingdom | ||
Regional investment funds are managed by North East Finance. | northeastfinance.org | Gateshead, United Kingdom | ||
Private equity investments are managed across the UK. | 1984 | nvm.co.uk | Newcastle Upon Tyne, United Kingdom | |
Investment management services are provided by Mercia to various clients. | 1982 | mercia.co.uk | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Newcells Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Newcells Biotech
10 people are tracked at Newcells Biotech (8 in leadership, 1 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Colin Brown | Chief Scientific Officer | Leadership |
Mike Nicholds | CEO | Leadership |
Simon Berry | Finance Director | Leadership |
Carolina Gándara | Principal Scientist, Head Of Retina Assay Development | Leadership |
Lyle Armstrong | Chief Scientific Officer | Leadership |
Valeria Chichagova | Associate Director of iPSC Technology & Head of Retina | Leadership |
John Burgess | Product Management & Marketing Director | Leadership |
Emile Shaffu | Global Sales Director | Leadership |
Peter Dines | Non-Executive Director | Board & advisors |
James Cartwright | Marketing & Content Executive | Team |
Complete people profiles for Newcells Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Newcells Biotech
3 dated milestones of Newcells Biotech across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Newcells Biotech is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $1.5M.
Web traffic of Newcells Biotech
The website of Newcells Biotech (newcellsbiotech.co.uk) receives about 5.2K visits a month.
- Monthly visits5.2K
▲ 56.1% vs previous month
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Newcells Biotech (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Newcells Biotech
Complete news archive for Newcells Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Newcells Biotech
Newcells Biotech was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Newcells Biotech is headquartered in Newcastle Upon Tyne, United Kingdom.
Newcells Biotech is a funded company, having raised a total of $14.43M across 9 funding rounds to date.
Newcells Biotech was founded in 2014 in Newcastle Upon Tyne, United Kingdom, within the biotechnology sector. Induced pluripotent stem cell-derived organoid models are created for research applications. Off-the-shelf products, such as neural progenitor cells and cardiomyocytes, are offered alongside custom reprogramming and differentiation services. These are provided to biopharmaceutical companies and research institutions to support drug development and scientific studies.
Newcells Biotech offers Retinal Organoids, Kidney Nephron Models, and Lung Airway Models.
Newcells Biotech has 6 investors. Key investors include Mercia, European Union, NVM Private Equity, Northstar Ventures, and North East Fund.
Newcells Biotech operates through Newcells Biotech Limited.
